Watson Continues Expansion Of Women’s Health Biz With Uteron Buy
This article was originally published in The Pink Sheet Daily
Watson has added a slew of products to its portfolio over the last three years to become a leader in the women’s health space. Its acquisition of Uteron gives it at least three more products for that portfolio.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.